NAPLEX Oncology Exams · Practice Exam 2
50 NAPLEX-style questions covering cancer biology, targeted therapies, monoclonal antibodies, endocrine therapy, leukemia and myeloma concepts, supportive care, and medication safety. Includes Study + Timed modes with full explanations for every question.
- 50 Questions
- 80 Minutes
- Study + Timed
- 39 SBA · 8 SATA · 3 Numeric
- Save & Resume
- Exam Tools
What this exam covers
Thirty-nine single-best-answer items with five options, eight select-all-that-apply items and three numeric fill-in items. Cancer biology from proto-oncogene activation and tumour-suppressor loss through chemotherapy-resistance mechanisms; treatment intent and the cell-cycle basis of drug selection; pharmacogenomics including DPYD testing before fluoropyrimidines; monoclonal-antibody targets, brand and generic recognition, and biosimilar reference products; administration and infusion-reaction management for rituximab, paclitaxel and pegaspargase; dose ceilings and capped doses; lenalidomide and hazardous-drug safety with immunisation considerations; acute promyelocytic leukaemia differentiation syndrome and arsenic QT risk; breast and prostate endocrine therapy including GnRH agonist flare and antagonist alternatives; CINV classification and breakthrough management; risk-stratified febrile neutropenia; and the calculations behind weight-based growth-factor dosing, capped vincristine doses and albumin-corrected calcium.
Included with eligible RxBoardPrep NAPLEX programs. Back to NAPLEX Oncology Exams
RxBoardPrep practice exams are independent educational study material. They are not affiliated with, endorsed by, or produced by NABP, they are not official NAPLEX questions, and the stated timing is RxBoardPrep practice timing rather than official examination timing.